| Literature DB >> 32343899 |
Parasuraman Rajasekaran1,2, David Crich1,2,3.
Abstract
The clinical aminoglycoside antibiotic gentamicin is a mixture of several difficult-to-separate major and minor components. The relative inaccessibility of the minor components in particular complicates efforts to separate antibacterial activity from nephro- and/or ototoxicity and to clarify the origin of the potentially therapeutically important read-through activity. With a view to facilitating such studies, the synthesis of a fully and selectively protected garamine-based acceptor has been developed from readily available sisomicin. Glycosylation of this acceptor with a 6-azido-6,7-dideoxy-d-glycero-d-glucoheptopyranosyl donor affords gentamicin B1 after deprotection, whereas employment of a 2-azido-2-deoxy-d-glucopyranosyl donor under N,N-dimethylformamide-directed glycosylation conditions affords gentamicin X2 after deprotection.Entities:
Year: 2020 PMID: 32343899 PMCID: PMC7237068 DOI: 10.1021/acs.orglett.0c01107
Source DB: PubMed Journal: Org Lett ISSN: 1523-7052 Impact factor: 6.005